MedTrace Logo

Evaluation of Efficacy of Lycium Barbarum Polysaccharide in Patients With Major Depressive Disorder

NCT04124276 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 284

Last updated 2020-10-30

No results posted yet for this study

Summary

Lycium barbarum, a traditional Chinese herbal medicine, is a commonly used herb in the traditional Chinese pharmacopoeia. Its main active ingredient, lycium barbarum polysaccharide (LBP), is reported to have neuroprotective effects. Animal studies suggested that LBP has neuroprotective effect on optic ganglion cells. In animal models of depression, LBP can improve depressive symptom by improving synaptic plasticity. However, its clinical effect remains to be studied. We will conduct a 6-week double-blind, randomized, placebo-con-trolled trial in patients with major depressive disorder (MDD). The purpose of this clinical trial is to investigate the efficacy of LBP in patients with MDD.

Conditions

Interventions

DIETARY_SUPPLEMENT

Lycium barbarum polysaccharide

Experimental groups take Lycium barbarum polysaccharide (LBP) (300mg/day) for 6 weeks

DIETARY_SUPPLEMENT

Placebo

Placebo control group takes placebo (300mg/day) for 6 weeks.

Sponsors & Collaborators

  • Fifth Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Guangzhou Psychiatric Hospital

    lead OTHER_GOV

Principal Investigators

  • Kangguang Lin, MD, PhD · Guangzhou Brain Hospital (Guangzhou Huiai Hospital)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2020-12-30
Completion
2021-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04124276 on ClinicalTrials.gov